FIELD: pharmacy. SUBSTANCE: invention relates to the combined preparation that can be used for treatment of patients with circulation system diseases. Preparation has an inhibitor of renin-angiotensin - cilazapril and an antagonist of endothelin - 4-tert.-butyl-N-[6-(2- -hydroxyethoxy)-5-(2-methoxyphenoxy)-1,2,2'-bipyrimidine-4-yl] - -benzenesulfoneamide at their mass ratio = (1: 1)-(1: 100), respectively. In part, the preparation has 2.5-10 mg of cilazapril and 250-1000 mg of endothelin antagonist. The total mass of both components in the preparation can be 550 mg. Combined administration of two components of the preparation results to the synergistic effect and therefore effective doses of both components can be decreased that diminishes adverse effects. EFFECT: enhanced effectiveness of preparation. 3 cl, 4 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
HYPOTENSIVE AGENT | 1992 |
|
RU2084225C1 |
SULFONEAMIDE DERIVATIVES AND PHARMACEUTICAL PREPARATION | 1996 |
|
RU2173317C2 |
PHARMACEUTICAL COMBINED PREPARATIONS | 1998 |
|
RU2222328C2 |
DERIVATIVES OF SULFONYLPYRROLIDINE | 2001 |
|
RU2272026C2 |
SULFONAMIDES AND PHARMACEUTICAL COMPOSITION | 1995 |
|
RU2151767C1 |
NOVEL REVERSE AGONISTS OF CB1 RECEPTOR | 2003 |
|
RU2339618C2 |
PIPERIDINE DERIVATIVES AND PHARMACEUTICAL PREPARATION BASED ON THEREOF | 1997 |
|
RU2184112C2 |
SULFONEAMIDOCARBOXAMIDES, THEIR HYDRATES AND PHYSIOLOGICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITION ON SAID | 1993 |
|
RU2133739C1 |
DERIVATIVES OF ARYL- AND HETEROARYLSULFONEAMIDES AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1995 |
|
RU2163598C2 |
RETINOIC ACID X-RECEPTOR LIGANDS | 1995 |
|
RU2146241C1 |
Authors
Dates
2000-03-20—Published
1994-07-14—Filed